Standard for Quantification of Pathogenic Aggregates from Endogenous Proteins

Simple SummaryContent extracted from patent full text and abstract with AI.

The patent describes the development of synthetic reference standards for accurately quantifying pathogenic aggregates or oligomers of naturally occurring proteins associated with neurodegenerative and protein misfolding diseases, such as Alzheimer's and Parkinson's disease. These standards are composed of polypeptide sequences that mimic the relevant disease-related aggregates but do not themselves form aggregates, ensuring reproducibility and stability in laboratory assays. Their unique structure enables precise calibration and quantification of pathogenic protein aggregates in biological samples.

Use CasesContent extracted from patent full text and abstract with AI.

• Development and standardization of diagnostic assays for detecting and quantifying pathogenic protein aggregates in neurodegenerative diseases like Alzheimer's, Parkinson's, and prion diseases.
• Calibration of laboratory instruments and measurement platforms (e.g., ELISA, surface FIDA, FACS) used in protein aggregation studies.
• Research on disease mechanisms by providing reliable standards for comparing experiments across different labs.
• Quality control and validation for clinical laboratory tests measuring protein oligomers in patient samples.
• Creation of kits for routine clinical diagnostics or research applications targeting protein aggregate quantification.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables highly accurate and reproducible quantification of pathogenic protein aggregates, improving sensitivity and specificity in diagnostic tests.
• Provides stable, homogeneous, and non-aggregating standards overcoming major limitations of previous methods, thus ensuring assay consistency over time.
• Facilitates comparability and harmonization of test results across different laboratories worldwide.
• Supports early and reliable diagnosis of neurodegenerative diseases, potentially before major clinical symptoms appear, thereby aiding timely intervention.
• Improves development and validation of new diagnostic technologies and therapies targeting protein aggregation diseases.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to standards for quantifying pathogenic aggregates or oligomers from proteins produced naturally in the body, which characterize a protein aggregation disease, an amyloid degeneration or protein folding aberration diseases, and to the use of said standards for quantifying said pathogenic aggregates or oligomers.